Lonigutamab
Based on 1 Customer Validation
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.00%
- CAS No.: 2362015-67-4
- Masse moléculaire:145.12 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
IGF1R/CD221
Lonigutamab (0-10 μg/mL, 6 d) induces nearly 100% cell death in IGF-1R-highly expressing MCF-7 (IC50 = 5.1×10-11 mol/L) and NCI-H2122 (IC50 = 6.25×10-10 mol/L) cells[1].
Lonigutamab (10 μg/mL, 10-120 min) exhibits rapid internalization in MCF-7 cellsand colocalizes with lysosomes[1].
Lonigutamab (10 μg/mL, 72 h) causes massive M-phase cell cycle arrest in MCF-7 cells and significantly increases the proportion of apoptotic and late necrotic cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCF-7, CaoV3, SBC5, NCI-H2122 and Hs746t cells were subcutaneously implanted into the flanks of 7-week-old female Swiss nude mice[1]
-
Dosage:3 mg/kg
-
Administration:i.v., once for four days, 4 cycles
-
Result:Achieved tumor growth inhibition.
Showed no significant changes in body weight.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 MCF-7 cells with Lonigutamab (HY-P99712, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2362015-67-4
-
Appearance Liquid
-
Masse moléculaire 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Lonigutamab]
-
Synonyms
hz208F2-4
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Akla B, et al. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. Mol Cancer Ther. 2020 Jan;19(1):168-177. [Content Brief]
[2]. Pimenta EM, et al. Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. bioRxiv [Preprint]. 2025 Jan 24:2025.01.20.633920. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lonigutamab Related Classifications
HY-P99712 Related Classifications
Powered by Bioz